Kinnear Pharma

Kinnear Pharma is a clinical-stage biotechnology company specializing in the development of inhaled therapies for respiratory infections. The company's primary asset, KP-001, is a dry powder inhalation formulation of gallium nitrate aimed at treating Pseudomonas aeruginosa infections in patients with cystic fibrosis. By exploiting the bacteria's requirement for iron, gallium nitrate acts as a mimetic that disrupts essential metabolic processes, providing a novel mechanism to combat antibiotic-resistant strains. In December 2021, Kinnear Pharma was acquired by Poolbeg Pharma, a clinical-stage infectious disease pharmaceutical company, to bolster its pipeline of respiratory treatments. The acquisition allows for the continued development of KP-001 through Phase 2 clinical trials, leveraging Poolbeg's expertise in infectious disease drug development.